Rolipram plays an anti-fibrotic effect in ligamentum flavum fibroblasts by inhibiting the activation of ERK1/2 [PDF]
BMC Musculoskeletal Disorders, 2021 Background Fibrosis is an important factor and process of ligamentum flavum hypertrophy. The expression of phosphodiesterase family (PDE) is related to inflammation and fibrosis.
Likang Wu +8 more
doaj +3 more sources
The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway [PDF]
Scientific Reports, 2021 Rolipram specifically inhibits phosphodiesterase (PDE) 4, thereby preventing inactivation of the intracellular second messenger cyclic adenosine monophosphate (cAMP).
Xiao-Liu Dong +3 more
doaj +3 more sources
A multifaceted examination of the action of PDE4 inhibitor rolipram on MMP2/9 reveals therapeutic implications [PDF]
Scientific ReportsA PDE4 (phosphodiesterase 4) inhibitor, Rolipram, was previously found to down-regulate (in a manner dependent on cAMP (cyclic adenosine monophosphate)-PKA (protein kinase A)) MMP2 (matrix metalloproteinase 2) and MMP9 protein expression levels ...
Arka Bagchi +3 more
doaj +4 more sources
Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis
Drug Design, Development and Therapy, 2022 Leila Gobejishvili,1 Walter E Rodriguez,1 Philip Bauer,2 Yali Wang,1 Chirag Soni,2 Todd Lydic,3 Shirish Barve,1 Craig McClain,1 Claudio Maldonado4 1Department of Medicine, School of Medicine, University of Louisville, Louisville, KY, USA; 2Endoprotech ...
Gobejishvili L +8 more
doaj +2 more sources
Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling [PDF]
International Journal of Neuropsychopharmacology, 2023 BACKGROUND Alzheimer's disease (AD) and depression often co-occur, and inhibition of phosphodiesterase-4 (PDE4) has been shown to ameliorate neurodegenerative illness. Therefore, we explored whether PDE4 inhibitor rolipram might also improve the symptoms
Yi-Fan Cong +7 more
openalex +2 more sources
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022 A few anti‐amyloid trials offer a slight possibility of preventing progression of cognitive loss, but none has reversed the process. A possible reason is that amyloid may be necessary but insufficient in the pathogenesis of AD, and other causal factors ...
Jeffrey Fessel
doaj +2 more sources
Rolipram, a PDE4 Inhibitor, Enhances the Inotropic Effect of Rat Heart by Activating SERCA2a
Frontiers in Pharmacology, 2019 This study was designed to investigate the hemodynamic effect of rolipram, a phosphodiesterase type 4 (PDE4) inhibitor, in normal rat hearts both in vivo and in vitro and its underlying mechanism.
Huili Huang +14 more
doaj +2 more sources
BMC Cardiovascular Disorders, 2020 Background Cardiac fibroblasts, regarded as the immunomodulatory hub of the heart, have been thought to play an important role during sepsis-induced cardiomyopathy (SIC).
Jingjing Ji +5 more
doaj +2 more sources
Rolipram Prevents the Formation of Abdominal Aortic Aneurysm (AAA) in Mice: PDE4B as a Target in AAA
Antioxidants, 2021 Abdominal aortic aneurysm (AAA) is a common life-threatening condition characterized by exacerbated inflammation and the generation of reactive oxygen species.
Saray Varona +10 more
doaj +2 more sources
Quantification of human brain PDE4 occupancy by GSK356278: A [11C](R)-rolipram PET study [PDF]
Journal of Cerebral Blood Flow and Metabolism, 2017 We characterized the relationship between the plasma concentration of the phospodiesterase (PDE)-4 inhibitor GSK356278 and occupancy of the PDE4 enzyme in the brain of healthy volunteers, using the positron emission tomography (PET) tracer [11C](R ...
Jasper van der Aart +9 more
openalex +2 more sources